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Solid tumors frequently coexist with a degree of local chronic inflammation. Recruited myeloid cells can therefore
be considered as interesting vehicles for tumor-targeted delivery of therapeutic agents. Using in vivo imaging, the
short-term accumulation of systemically injected monocytes, macrophages and myeloid-derived suppressor cells
(MDSCs) was compared in mice bearing fat pad mammary carcinomas. Monocytes and macrophages
demonstrated almost identical in vivo and ex vivo distribution patterns with maximal tumor-associated
accumulation seen 48 hours after injection that remained stable over the 4-day follow-up period. However, a
substantial accumulation of both cell types was also seen in the liver, spleen and lungs albeit decreasing over time
in all three locations. The MDSCs exhibited a similar distribution pattern as the monocytes and macrophages, but
demonstrated a better relative on-target fraction over time. Overall, our findings highlight off-target cell
accumulation as a major obstacle in the use of myeloid cells as vehicles for therapeutic tumor-targeted agents and
indicate that their short-term on-target accumulation is mainly of nonspecific nature.
Neoplasia (2018) 20, 848–856dress all correspondence to: Prof. Dr. Niek N. Sanders, Laboratory of Gene
erapy, Department of Nutrition, Genetics and Ethology, Faculty of Veterinary
edicine, Ghent University, Heidestraat 19, B-9820 Merelbeke, Belgium.
mail: Niek.Sanders@ugent.be
ceived 10 March 2018; Revised 16 June 2018; Accepted 19 June 2018
2018 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open
cess article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
76-5586
tps://doi.org/10.1016/j.neo.2018.06.005troduction
any cancers are intrinsically linked to an inflammation reaction
sociated with the recruitment of white blood cells. Consequently,
ing myeloid cells as intelligent drug carriers for intricate sensing and
nditional release/expression of therapeutic cargoes has been a long-
sired goal [1,2]. Ideally, this strategy would concentrate the
erapeutic substances at the tumor site avoiding high systemic levels,
ading to wider therapeutic windows and hence, better cancer drug
fety profiles [3]. Currently, white blood cells are already used as
mplex vehicles to manipulate a diverse set of biologic processes, as
monstrated by the recent success of CAR T cell therapy [4]. Since
e feasibility of engineering immune cells to treat cancer was
monstrated, the focus shifted towards optimization studies. An
inent need for fundamental studies on biodistribution of cell-based
erapeutics or cellular drug delivery vehicles emerged [4,5]. In this
ntext, several “tumor-homing” cell types such as tumor-infiltrating
mphocytes (TILs) [3], neutrophils [3,6], mesenchymal stem cells
SCs) [7] and myeloid-derived suppressor cells (MDSCs) [8] have
en investigated. Although the validity of the homing concept waspeatedly demonstrated, most of these migration studies selectively
cused on the tumor-specific accumulation. However, information
the accumulation of these cellular vehicles in off-target tissue is
ited. As pathologically activated leukocytes of the myeloid lineage
ch as tumor-associated macrophages (TAMs) [9] and MDSCs [10]
e known to accumulate in massive numbers in the tumor
icroenvironment, the current study evaluated their migration
tterns. More specifically, the aim was to assess whether off-target
cumulation of these injected myeloid cells forms a barrier in the
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ticancer agents.
DiR (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine
dide) is a non-immunogenic lipophilic carbocyanine near infrared
IR) dye that is frequently used for in vivo migration studies
1-14]. After integration into lipid membranes, DiR becomes a very
ight NIR dye that allows non-invasive tracking of labelled cells for
veral days without interfering with their biological function
1,12,15]. In the current study, DiR was used as labelling agent
r comparing short-term tumor-tropism of primary monocytes,
acrophages and MDSCs. In a murine orthotopic 4T1 mammary
enocarcinoma model, all these myeloid cell types displayed clear
sual accumulation in the primary tumors after systemic adminis-
ation. However, substantial off-target cell sequestration in the liver,
leen and to a minor extent also in the lungs was observed as well.
his latter aspect should not be ignored when considering these
llular vehicles for the delivery of cytotoxic agents.m
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nimals
All procedures in this study were approved by the Ethical
ommittee of the Faculty of Veterinary Medicine and the Faculty
Bioscience Engineering of Ghent University, Belgium (EC 2015/
0). Female BALB/cJRj mice, aged 6-8 weeks, were purchased from
nvier Labs (Paris, France) and housed in a temperature and
midity controlled room while being kept on a 12h:12h reverse
ht/dark cycle. Ad libitum access to low-fluorescence food (Envigo,
oxmeer, Netherlands, #T.2018.12) and water was provided. Mice
ere ear marked and randomly assigned to experimental conditions.
ll manipulations were performed on a heated platform and under
neral anesthesia using 5% isoflurane (Zoetis, Louvain-la-Neuve,
elgium, #B506) at 4 L/min oxygen for induction and 1.5-2%
oflurane at 0.5-1 L/min oxygen for maintenance.
umor Model
Luciferase-positive 4T1 mammary carcinoma cells were cultured in
mplete medium consisting out of DMEM/F12 (Gibco, #21041-025)
pplemented with 10% heat inactivated FBS (Biowest, #S181H-500)
d 1% penicillin/streptomycin (Gibco, #15070-063). After at least 3
ssages, cells were trypsinized and washed twice in Dulbecco's
osphate-Buffered Saline (DPBS, (Gibco, #14190-144). Subsequently,
105 cells in 100 μl DPBS, were injected in the 4th right fat pad using a
G insulin syringe (Terumo, Leuven, Belgium, #BS05M2913). Tumor
owth was verified by administering 200 μl D-luciferin (15 mg/ml
PBS) (Goldbio, St-Louis (MO), USA, #LUCK-1G) subcutaneously
llowed by bioluminescence imaging after 10 min with an IVIS Lumina
system (PerkinElmer). Cell migration experiments were initiated
days post tumor inoculation. At this timepoint, tumors reached an
erage diameter of 4.73mm (range 3.77mm to 6.18mm). This average
mor diameter was obtained bymeasuring both perpendicular diameters
ice and then averaging the total of 4 measurements.
rimary Cells
Bone marrow cells were isolated from female BALB/cJRj mice
cording to the method described by Amend et al. (2016) [16]. Mice
ere induced with isoflurane and sacrificed via cervical dislocation.
ext, femurs and tibias were dissected, sterilized 10 seconds in 70%
isinfectol (Chem-lab NV, Zedelgem, Belgium, #CL00.0112.2500)d rinsed in sterile DPBS before snapping the bones in half and
ansferring these to punctured 0.5 ml Eppendorf tubes that were
aced in empty 1.5 ml EP tubes. After centrifugation for 15 seconds
10,000xg, recovered pellets were resuspended 40 seconds in ACK
BC lysis buffer (Gibco, #A10492-01) and neutralized by
ansferring the solution to 10 ml DPBS. Finally, these cells were
ntrifuged for 5 min at 400xg and resuspended in complete medium.
Monocyte-derived cells were obtained by seeding RBC-depleted
ne marrow cells (4x106 cells/4 ml per dish) in complete medium
pplemented with 20 ng/ml M-CSF (VWR, Leuven, Belgium, #21-
83-U010). To drive monocyte-derived cells towards differentiation
macrophages—hereafter referred to as ‘macrophages’—cells were
ltured for 7 days in 9 cm untreated petri dish (allowing easier
tachment) [17] (VWR, Leuven, Belgium, #734-2311). Macro-
ages were collected via mechanical dissociation with cell scrapers
WR, Leuven, Belgium, #734-2602) after washing in 10 mM
DTA (Gibco, #15575-038) in DPBS and adding complete
edium. Monocyte-derived cells intended to maintain a more
mature monocyte status—hereafter referred to as ‘monocytes’—
ere cultured for only 5 days in 6-well ultra-low attachment plates
igma-Aldrich, Overijse, Belgium, #CLS3471-24EA) to prevent
herence-induced differentiation [18]. Culture medium was
freshed 3-4 days post-seeding. Only the monocytes in suspension
ere collected for further experiments. Experiments with ‘Antigen-
perienced’monocytes were also performed and these were obtained
incubating monocytes with 106 lysed (freeze-thawed twice) 4T1
lls per well 24 h prior to injection.
Primary MDSCs were obtained by harvesting bone marrow cells
ter RBC lysis from female Balb/cJrj mice bearing a 14-day old 4T1
mor. Ex vivo differentiated MDSCs were obtained by culturing
esh RBC-depleted bone marrow cells from healthy mice (see above)
days on 6-well plates in GM-CSF supplemented 4T1-conditioned
edium (Navarrabiomed, Pamplona, Spain) complemented with
% FBS, 1% penicillin/streptomycin and 0.5% gentamycin
hermoFisher, #15710-049) according to the manufacturer’s
structions and as described by Lichtenstein et al. (2014) [19,20].
ell Labelling
Labelling with DiR (Life, Eugene (OR), USA, #D12731) was
rformed by adding 5 μMdye (final concentration) to cells suspended
DPBS at a concentration of 1x106/400 μl. After gentle mixing, the
lls were incubated for 20 min at 37°C in darkened 15 ml tubes.
bsequently, they were washed twice in at least 4 volumes of cold
mplete medium before suspending in appropriate downstream buffer
PBS for injection or staining buffer for flow cytometry).
stemic and Local Injection
Labelled cells were gently vortexed prior to injection with a 29G
sulin syringe. Unless noted otherwise, 100 μl of cells suspended in
PBS were injected in the right orbital plexus of anesthetized mice at
concentration of 10x106/ml [21-24]. Local injection occurred
rough intratumoral injection of 105 DiR-labelled monocytes (in
μl DPBS) into 10-days old 4T1 tumors.
rgan Dissociation
Twenty-four hours after injection of the DiR-labelled cells, mice
ere euthanized and the liver, spleen, lungs, uterus, kidneys, left 4th
ammary gland (tumor-free contralateral control), heart, intestines
d primary tumor were collected for each mouse. Subsequently, the
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850 Off‐Target and Tumor‐Specific migration of injected myeloid cells Combes et al. Neoplasia Vol. 20, No. 8, 2018ngs, spleen, liver and primary tumor were dissociated using a
ntleMACS system (Miltenyi, Cologne, Germany, #130-093-235),
llowed by 45 min enzymatic digestion at 37°C in the presence of
NaseI (Worthington, Gestimed Brussels, LS006342, 10 U/ml final
ncentration) and collagenase IV (Worthington, Gestimed Brussels,
S004186, 100 U/ml final concentration) in DMEM/F12. The
sulting single cell suspensions were washed twice in DMEM/F12
or 5 min at 400xg centrifugation) followed by passing them through
70 μm cell strainer (Falcon, #352350).
low Cytometry
Cells were suspended at 1×106/ml in 200 μl staining buffer (DPBS +
FBS + 2mM EDTA) followed by adding 0.5 μl anti-CD16/32 FcR
ocking antibodies (BD, #553142) [25]. After 10 min incubation at 4°C
ditional fluorescently labelled antibodies against the selected markers
ere added and the cells were further incubated at 4°C for 15 min.
bsequently, they were washed by adding 1 ml staining buffer per dark
5 ml EP tube and centrifuged for 5 min at 400×g. The resulting pellet
as resuspended in 200 μl staining buffer. The DNA intercalating dye 7-
AD (Biolegend, #420403) was used to exclude dead cells. A weekly
librated and validated C6 Accuri (BD) or Cytoflex (Beckman Coulter)
w cytometer was used for acquisition. BD Accuri C6 software (version
0.264.21) and Cytexpert 2.0 were used for analysis, respectively.
llowing selected antibodies were used (all from Biolegend): anti-Ly6C-
TC (#128005), anti-Ly6G-PE (#127607), anti-CD11b (#101211),
ti-MHC II-APC (#107613) and anti-CD115 PE (#135505), while
ti-F4/80-R-PE was ordered from Biorad (#MCA497PET). Used
otypes (all from Biolegend) were: Rat IgG2c,κ (#400705), Rat IgG2a,κ
400507) and Rat IgG2b,κ (#400612).
Vivo and Ex Vivo Fluorescence Imaging
In vivo fluorescence imaging of the DIR-labelled cells was
rformed with an IVIS Lumina II system (PerkinElmer) using the
5/820 nm filter pair. All mice were ventrally shaven from the
rvical to the pubis region before imaging. After in vivo fluorescence
aging, the accumulation of the labeled cells in the tumor and liver/
leen was quantified using the formula:
ccumulation factor ¼ Organpost=Mampost
 
Organpre=Mampre
 
Where Organpost stands for total fluorescence efficiency (TFE) in the
gion of interest (ROI) drawn around either the tumor or the liver-and-
leen after injection of the DiR-labelled cells. In most mice, liver and
leen could easily be discriminated, but since spleenmobility can cause
leen and liver to overlap in vivo, the fluorescence of these organs was
mbined into one ROI.Mampost stands for the TFE in the ROI drawn
ound the naive (tumor-free) mammary gland after injection of DiR-
belled cells. Similarly,Organpre andMampre both represent the TFE in
e respective ROI, but before injection of DiR-labelled cells. ROI
mensions were kept constant for all mice. This formula essentially
scribes the normalized fold change of TFE in the tumor and liver-
d-spleen upon injection of the DiR-labelled cells.
Ex vivo fluorescence signal of the organs and tumors were
antified using the formula:
old increase ¼ Organlabelled
OrganunlabelledWhere Organlabelled stands for the TFE in the ROI drawn around
organ after labelled cells were injected. Organunlabelled stands for the
FE in the ROI of the same respective organ of another mouse which
ceived an equal number of unlabelled cells. ROI dimensions were
pt constant for all mice. This formula essentially describes a
orescence fold increase value of organs after injection of labelled
lls. A fold increase value of 1 means that no change has occurred.
tatistics
Statistics were performed via Prism Graphpad (version 6.01).
nless otherwise specified, two-way ANOVA (using time and
ndition or time and organ as factors) followed by Tukey’s test for
ultiple comparisons was used in most experiments. A threshold of
0.05 (corrected for multiple comparisons) was used to test for
atistical significance. Reported values represent averages ± standard
viation (SD).esults
Vivo Migration of Monocytes and Macrophages
Monocyte-derived macrophages accumulate in massive numbers in
e tumor microenvironment [5, 26, 27]. These so-called TAMs are
erefore interesting vehicles for tumor targeted delivery of e.g.
erapeutic genes. However, the extent to which they specifically
cumulate in the tumor after systemic injection remains unclear. The
vivo distribution of systemically injected DiR-labelled, bone
arrow-derived monocytes (n=5) and macrophages (n=5) was
vestigated in 4T1 tumors with an average diameter of 4.78±
73 mm. Immunophenotypic profiles of these in vitro differentiated
onocytes and macrophages showed the expected expression of the
yeloid marker CD11b (93.2% and 82.4%, respectively) and the
onocytic lineage marker F4/80 (62.9% and 72.8%, respectively) in
th subsets. Further characterization using monocyte/macrophage
aturation markers Ly6C and MHC II demonstrated a less
fferentiated status of monocytes (Ly6ChiMHCIIlo) compared to
acrophages (Ly6CintMHCIIhi) (Supplementary Figure 1). DiR-
belled monocytes and macrophages were intravenously injected and
eir distribution was subsequently monitored over 96 h by in vivo
orescence imaging (Figure 1). Twenty-four hours post injection,
th monocytes and macrophages demonstrated a clear visual
ildup of fluorescence in all tumors. During the follow-up period,
e number of accumulated monocytes and macrophages remained
most constant with average accumulation factors ranging from 1.89
2.35 (±0.19) to 2.19—2.37 (±0.08) for monocytes and macro-
ages, respectively. No significant differences in tumor accumula-
on factor between the two cell types were observed (p≥0.922).
owever, a strong off-target accumulation of these cells was seen in
e liver and spleen. The total fluorescence in these off-target organs
as significantly higher compared to that in the tumors (pb0.0004),
ith average accumulation factors ranging from 4.09 – 5.18 (±0.55)
4.76—5.37 (±0.26) for macrophages and monocytes, respectively.
milar to the primary tumor, this combined total in vivo fluorescence
the liver-and-spleen did not demonstrate significant differences
tween monocytes and macrophages (p≥0.976). However, in
ntrast to the primary tumor, a slight decrease in fluorescence over
me was noticed in the liver and spleen. One mouse in the
acrophages group was removed from the analysis since its primary
mor spontaneously disappeared at the start of the 4-day follow up
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Figure 1. In vivo fluorescence signal in tumors (red) or liver and spleen (blue) upon injection of 1x106 DiR-labelled monocytes (broken line,
asterisks) or macrophages (full line, dots). (A) Representative images of two mice 48 h after systemic injection of DiR-labelled monocytes
or macrophages. Primary tumors develop in the 4th right abdominal mammary gland. (B) Graph showing the time-dependent DiR
fluorescence in the tumor and liver/spleen. Depicted values in the Y-axis represent the in vivo accumulation factor i.e. the corrected
fluorescence signal taking into account differences in background fluorescence in the tumor and the liver/spleen (see Materials and
methods section). A value of y=1 indicates no increase in fluorescence signal in the tissue compared to the signal before injection of the
labelled cells. (*** pb0.0001), n=5. Tumour (T), liver (L), spleen (S).
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Neoplasia Vol. 20, No. 8, 2018 Off‐Target and Tumor‐Specific migration of injected myeloid cells Combes et al. 851riod. Interestingly, this process was accompanied with a concurrent
ss of fluorescence. In Supplementary Figure 2 the complete line-up
all mice before and 48 h after injection of labelled monocytes or
acrophages is depicted.
Ninety-six hours after injection, all mice were sacrificed with an
erage end-stage tumor diameter of 5.98 mm (±0.74). Ex vivo
orescence imaging was performed on the dissected tumors and
gans (Figure 2 and Supplementary Figure 3). In line with the
vivo fluorescence, a similar tissue accumulation pattern of the
onocytes and macrophages was observed. Monocytes demonstrated
5.53 (±0.69) fold increase at the tumor location, whereas
acrophages exhibit a 7.07 (±0.98) fold increase. However, ex vivo
aging allowed to identify the liver as the main organ of fluorescence(S
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gure 2. Ex vivo fluorescence signal at 96 h in the liver, spleen,
ngs and tumor depicted as fold increases over background
orescence in the respective tissues of mice that were injected
ith unlabelled cells. Dotted line at y=1 indicates no change in
orescence. Significant difference between monocytes and
acrophages are only detected in the liver (*p=0.0262). Within
e cell type, all organs exhibit significantly different fluorescence
≤0.0262) except for tumor versus lungs (both monocytes and
acrophages) and liver versus spleen (monocytes). n=5cumulation with a 30.00 (±6.16) and 37.85— (±4.95) fold increase
er background for monocytes and macrophages, respectively. This
as the only significantly different (pb0.0262) organ value for both
ll types. In addition to the liver, the spleen was confirmed as the
cond important organ were the injected cells accumulate with an ex
vo fold increase of 27.40 (±3.36) and 25.30 (±2.49) for monocytes
d macrophages, respectively. Ex vivo imaging further identified the
ngs as an important organ of signal retention with fold increases of
34 (±0.83) and 7.46 (±1.55) for monocytes and macrophages,
spectively, being in the same range as the signals measured in the
imary tumor (Figure 2).
We also evaluated tumor migration of unstimulated monocytes
rsus antigen-experienced monocytes in tumor-bearing mice
upplementary Figure 4, A-C). Until 4 days post injection,
tigen-experienced monocytes accumulated significantly more in
e liver-and-spleen compared to unstimulated monocytes. No
fference in tumor-homing was detected. In addition, we also
udied the fate of DiR-labelled monocytes after intratumoral
jection in 4T1 tumors. No leakage of DiR fluorescence to the
er and the spleen was detected, indicating high tumoral retention of
e injected monocytes (Supplementary Figure 4D).
Vivo Assessment of Possible Artefacts
In a subsequent set of experiments, the extent to which artefacts
uld have affected our data was studied. Three control experiments
ere performed. In a first control experiment we determined whether
sidual free DiR could cause artefacts in the migration pattern. This
as done by injecting the supernatant obtained after washing of DiR-
belled macrophages. The second control experiment involved the
jection of lysed DiR-labelled macrophages to quantify nonspecific
ll debris accumulation. Additionally, we also wondered whether the
mor accumulation of the monocytes/macrophages could be
tributed to an active migration process. Therefore, in a third
ntrol experiment, the chemotaxis receptors on the macrophages
ere inactivated by fixing them with paraformaldehyde and injecting
ese fixed DiR-labelled macrophages. The injected numbers of lysed
fixed macrophages were equal to the number of injected live
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Figure 3. (A) Comparison of the in vivo accumulation factor and (B) the ex vivo fold increase in the liver, spleen, lungs and tumor of live,
fixed and lysed DiR-labelled macrophages 24 h after their systemic injection. n=4 (live cells), n=2 (controls).
852 Off‐Target and Tumor‐Specific migration of injected myeloid cells Combes et al. Neoplasia Vol. 20, No. 8, 2018acrophages. To allow a proper comparison, live DiR-labelled
acrophages were also repeated in this experiment.
For all three controls, the in vivo organ-associated accumulation
ctor and the ex vivo fold increase value was evaluated 24 h after
jection (Figure 3). Injection of supernatant did not result in
creased fluorescence in the tumor (0.92 ±0.10, p≥0.9113), or in the
er and spleen (1.00 ±0.02, p≥0.9623), demonstrating that the
fect of possible residual free dye in the cell suspension can be
nsidered irrelevant (data not shown). Corroborating the data from
r previous experiment, live DiR-labelled macrophages are
sociated with the highest in vivo accumulation factor in the
mor (1.40 ±0.18) and in the liver-and-spleen (4.13 ±0.77) (blue
rs Figure 3A). This was further supported with ex vivo fold increase
lues of 26.31 ±6.11, 17.90 ±4.37 and 1.72 ±0.14 for liver, spleen
d tumor, respectively (Blue bars Figure 3B). Similar to the live cells
=0.4168), systemic administration of labelled cell debris (lysed
lls) mainly resulted in a high in vivo accumulation factor in the liver
d spleen (3.27 ±0.74, yellow bars Figure 3A). This concordance with
e cells was also reflected in the ex vivo fold increase values of the liver
d the spleen (25.88 ±17.04 and 10.14 ±4.88, respectively; yellow bars
igure 3B). As expected, the small cell fragments present in lysed cells
used a much lower accumulation in the lungs (3.85 ±1.62).
ompared to live cells, lysed cell debris appeared to be slightly less
esent at the tumor location in vivo (1.14 ±0.03), a measurement that
uld not be verified ex vivo since all conditions led to similar ex vivo
ld increase values (1.72-1.73 ±0.22) (Figure 3 and Supplementary
igure 5). This equal tumor-associated fluorescence further substanti-
ed the hypothesis of nonspecific accumulation in the tumor. The
mber of dead cells in our inoculum was determined to vary between
-15% (Supplementary Table 1). Considering the weak tumor
cumulation of cell fragments and the low percentage of dead cells in
r inoculum, the effect of dead cells on the tumor accumulation is
ely negligible. Still, a small percentage of the off-target accumulation
the immune cells could be attributed to dead cells.
In vivo, fixed cells accumulated to a similar extent as live cells in the
mor (1.28 ±0.18, pN0.9999), indicating that tumor-associated
cumulation is of passive rather than active nature. In marked
ntrast to live cells and lysed cells, fixed cells exhibited a much lower
vivo accumulation in the liver and spleen (1.79 ±0.06, p=0.0012,
d bars Figure 3A). The decreased number of fixed cells in the liver
.32 ±1.23) might be clarified by a marked presence of these cells in
e lungs (17.85 ±8.58, p=0.9132, red bars Figure 3B). The ex vivo
orescence data shown in Figure 3B were further confirmed via flow
tometric analysis on single cell suspensions (Supplementary Figure 5).Vivo Migration of Myeloid Derived Suppressor Cells
Myeloid derived suppressor cells (MDSCs) are immature bone
arrow-derived myeloid cells that cause immunosuppression and are
ecifically recruited by solid tumors [8,28]. In particular, mice
aring 4T1 mammary tumors have been demonstrated to possess a
markable high number of MDSCs in their bone marrow compared
naive mice [29-33]. Therefore, it was studied whether the
stribution of in vitro differentiated MDSCs [20] or MDSCs obtained
om 4T1 tumor-bearing mice showed a different tumor tropism and
stribution compared to bone marrow cells of healthy mice after
stemic injection (Figure 4). Flow cytometric immunophenotyping
ior to injection (Supplementary Figure 6) indicated that bonemarrow
om 4T1 tumor-bearing donors consisted mainly of myeloid cells
2.8% CD11b+), with a majority of these CD11b+ cells being of the
anulocytic MDSC phenotype (22.5% CD11b+Ly6G+Ly6Cint) and
a lesser extent of the monocytic MDSC phenotype (3.6%
D11b+Ly6G-Ly6Chi). Similarly, the granulocytic phenotype was
so overrepresented in the in vitro differentiated MDSCs (44.8%
rsus 8.0% monocytic phenotype within the 90.8% CD11b+
pulation). In contrast, the bone marrow originating from healthy
nors contained a far lower percentage of CD11b+ cells (27.5%) of
hich only 14.3% were CD11b+Ly6G+Ly6Cint and 2.4% were
D11b+Ly6G-Ly6Chi cells.
At the tumor site, maximal accumulation of the three types of cells
mained limited and occurred at later timepoints: the 4T1 tumor-
aring donor derived and in vitro differentiated MDSCs exhibited
aximal tumor accumulation factors after 48 h (1.46 ±0.22) and 72 h
.35 ±0.17), respectively; while the signal of healthy donor bonemarrow
lls continued to increase up until the last timepoint, reaching a tumor
cumulation factor of 1.55 (±0.02) (Figure 4A).
Similar to the monocytes and macrophages, the highest accumu-
tion of all MDSC types was observed in the liver and spleen at 24 h.
his maximal in vivo accumulation factor was higher for the in vitro
fferentiated MDSCs (2.80 ±0.62) than for the healthy donor bone
arrow cells (2.36 ±0.25) and the 4T1 tumor-bearing donor-derived
DSCs (1.81 ±0.11). At later timepoints, the accumulation factors
the liver and spleen showed a steady decline reaching respective
lues of 1.88 (±0.26), 1.77 (±0.14) and 1.36 (±0.16) 96 h after
jection (Figure 4B).
omparing Relative On-Target Migration of Monocytes,
acrophages and MDSCs
The overall trend in all evaluated myeloid cell types was a time-
pendent decrease in off-target accumulation (liver and spleen) and a
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Figure 4. In vivo accumulation factors in tumors (A) or liver and spleen (B) upon injection of DiR-labelled bone marrow cells from a healthy
donor (‘BM’, red, dots), MDSCs from a 4T1 tumor-bearing donor (‘4T1 BM’, yellow, triangles) or in vitro differentiated MDSCs (‘MDSC’,
blue, asterisks). At almost all timepoints, these three types of cells accumulated equally in the tumors and in the liver and/or spleen.
Significant differences at the tumor 96 h after injection between BM and 4T1 BM (p=0.0489) and at the liver-and-spleen 24 h after injection
between MDSCs and 4T1 BM (p=0.0003). A value of y=1 indicates no increase in signal. MDSCs: myeloid-derived suppressor cells. n=5.
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well as Figure 4. Figure 5 depicts this relationship as a ‘relative on-
rget’ graphwhere the tumor-associated accumulation, quantified by the
vivo accumulation factor, of each cell type is represented as the
rcentage of the combined signal present in the tumor versus liver and
leen. At the end of the 4-day follow-up period, MDSCs from a 4T1
mor-bearing donor (48.3% ± 4.4% at 96 h), and bone marrow cells
om healthy donor mice (46.8% ±2.1% at 96 h) and in vitro
fferentiated MDSCs (42.1% ± 4.4% at 96 h) exhibited a higher on-
rget migration than primary monocytes (34.2% ± 3.7% at 96 h) and
acrophages (32.8% ± 6.6% at 96 h).co
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em cells, more specifically MSCs, are vigorously pursued to serve as
mor-targeted cellular vehicles due to their immune-privileged andre
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gure 5. Relative percentage of on-target tumor accumulation of
e myeloid cells where the tumor-associated accumulation,
antified by the in vivo accumulation factor, of each cell type is
presented as the percentage of the combined signal present in
e tumor versus liver and spleen (tumor/(tumor + liver and
leen)). Significant differences: monocytes versus MDSCs from
1 tumor-bearing donor (at 24 h, 72 h and 96 h; pb0.05),
onocytes versus bone marrow cells from healthy donor (at 96 h,
0.05), monocytes versus in vitro differentiated MDSCs (at 48 h,
0.05), macrophages versus bone marrow cells from healthy
nor (at 96 h, pb0.05) and macrophages versus MDSCs from 4T1
mor-bearing donor (at 96 h, pb0.01). MDSCs: myeloid-derived
ppressor cells.vasive characteristics. These characteristics enable MSCs to be used
allogeneic settings [34]. Moreover, they have been demonstrated to
cumulate at the microenvironment of solid tumors. Tempering this
omising effect, several groups have observed that only a limited
mber of injected MSCs reach the tumor and that their main
erapeutic properties can be largely attributed to the secretion of
luble factors [7,35,36]. This major caveat led us to explore other cell
pes which could be used as tumor-targeted vehicles. Particularly
yeloid leukocyte subsets have been demonstrated to gather in large
mbers in the tumor microenvironment. For example, tumors of 4T1
mor-bearing mice are characterized by a CD45+ cell population
nsisting mainly out of myeloid cells (70-90%) and only 2.4–7%
D3+ T cells [37-39].Most of themyeloid cells in thismodel have been
entified as TAMs (40%) or tumor-associated neutrophils (TANs,
%) and only a small percentage were dendritic cells (b5%) [39].
deed, to successfully establish an immunosuppressive milieu,
cruitment of TAMs and MDSCs seems indispensable for solid
mors [40-42]. We therefore reasoned that these myeloid cells are
tentially useful as tumor-targeted cellular vehicles. Classically,
onocytes are believed to exhibit superior trafficking properties
mpared to further differentiated macrophages [43,44]. Nevertheless,
on systemic injection of monocytes or macrophages we observed a
arly identical in vivo distribution pattern. The normalized accumu-
tion factors demonstrated that both cell types exhibited a clear tumor-
sociated accumulation 24 h after injection. This accumulation
mained stable (or slightly increased) over the 96 h follow-up period.
portantly, both cell types also demonstrated substantial off-target
igration to the liver and the spleen. This off-target accumulation in the
er-and-spleen was significantly higher compared to the tumor-
sociated value and it steadily declined over the 96 h follow-up period.
his indicates a continuous clearance of the injected cells from the liver
d/or spleen. Ex vivo fluorescence imaging at 96 h post injection
entified the liver, followed by the spleen, as the two main organs for
ll retention. The lungs were identified as a third organ where labelled
lls accumulated after systemic injection. An equal accumulation of
onocytes and macrophages was observed in almost all organs and no
levant differences in trafficking behavior between monocytes and
acrophages could be identified [3,45-47]. Furthermore, experiments
mparing the tumor migration behavior of tumor antigen-experienced
onocytes with unstimulated monocytes did not reveal any significant
fferences either. Nonetheless, a higher tendency of antigen-experienced
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e first 4 days after systemic injection. Upon intratumoral injection of
iR-labelled monocytes, we could measure the DiR fluorescence for at
ast 3 weeks post injection without clear indications of leakage to the liver
d/or the spleen. Over this period, a linear 3-fold decrease in DiR
orescence was detected most probably due to degradation of the
acking dye rather than redistribution of labelled cells.
The similarities between monocyte and macrophage distributions
ggest a tendency of systemically injected cells to accumulate in a
n-specific manner. One can argue that that the similar distribution
the current study might in part be attributed to the lack of
fficient immunophenotypic differences between both populations.
deed, even though the macrophages demonstrated a relatively more
ature phenotypic profile based on the classical maturation markers
4/80+/Ly6C+/MHC II+), the injected macrophages still contained
lls with a phenotypic profile of less mature monocytes. This
terogeneity is inherent to the used culture methods to generate
acrophages or monocytes. Perhaps further separation of the
onocytes and macrophages by a MACS-based negative selection
otocol could have resulted in a more different migration pattern [48].
Our data corroborate the work of Ritchie et al. (2007) who
ported that infused macrophage-activated killer (MAK) cells first
cumulate in the liver, lungs and to a minor degree in the spleen,
ter which redistribution occurs from the pulmonary vasculature to
her tissues including peritoneal metastases [49]. In line with this
udy and two other independent studies describing pulmonary
distribution of macrophages or MSCs, we also noticed a higher
mber of macrophages in the lungs 24 h after injection compared to
h after injection [5,36,49]. These kinetics may indicate that, also
our study, systemically injected macrophages are first partly
questered in the lungs after which redistribution of these captured
lls occurs to off-target organs such as the liver and the spleen as well
to on-target malignant sites. Supporting the current findings,
itchie et al. (2007) described a much higher off-target versus on-
rget accumulation of these MAK cells as well. However, these
thors report constant levels of MAK cells in liver and spleen, while
e monocytes and macrophages in our study gradually declined in
ose organs. A possible explanation for this difference could be the
fference in activation status upon injection i.e. their use of IFNγ-
ediated macrophage activation as opposed to our use of
stimulated monocytes and macrophages.
To evaluate whether our immune cells actively migrate to tumors
e subsequently inhibited the active migration capacity of macro-
ages by fixation. Surprisingly, the tumor migration of fixed
acrophages did not differ from that of unfixed ones. This may
dicate that the migration of the macrophages towards the tumors is
passive rather than an active process. Interestingly, fixed
acrophages showed an increased retention in the lungs compared
their unfixed counterparts. Fixed macrophages have a lower
pacity to deform and hence may cause a higher obstruction of the
all lung vessels [50]. Despite the increased retention of the fixed
acrophages in the lungs, no symptoms of pulmonary embolization
ere noticed.
The massive migration of injected monocytes and macrophages to
e liver and spleen warranted to investigate whether some of the
served fluorescence could be attributed to labelling artefacts. DiR, a
ophilic NIR dye, integrates in cell membranes after short
cubation with the cell suspension. As a result, dead cells or cell
agments originating from dead cells are also labelled with this dyed could partially mask the live cell-associated fluorescence.
herefore, the distribution of DiR-labelled dead cells/cell debris
as assessed. As expected, this debris appeared to pass the lung
pillary bed more easily than whole cells, but got captured—
obably by the reticuloendothelial system—in the liver and spleen.
ead cells/cell fragments also accumulated in the tumors, although
ere was a non-significant trend of lower in vivo accumulation in the
mor than the live cells. These data illustrated that DiR labelling
tefacts originating from labelled dead cells/cell fragments should not
ignored when considering the in vivo distribution of live cells.
owever, since only a limited number of dead cells/cell fragments
round 10%) were injected in our experiments, we only expect a
inor impact on our migration data. Additionally, flow cytometry on
ngle cell suspensions of the different tissues confirmed that viable
iR-labelled cells were present in the tumor, liver, spleen and lungs
ter intravenous injection of DiR-labelled macrophages. Another
ncern was the potential residual dye remaining in the supernatant
injected cell suspensions. Hypothetically, it could label cells in vivo
.g. hematopoietic cells or endothelial cells). However,
e demonstrated that residual free dye in the cell suspension did
t increase the fluorescence in the tumor and tissues above
ckground.
Besides MSCs, monocytes and macrophages, MDSCs have also
en exploited in several studies for their superior tumor-homing
operties [8,51-54]. Eisenstein et al. (2013) reported monocytic
DSCs to significantly outperform other leukocyte subsets such as
ïve T cells or IL-2 activated T cells, monocytes, macrophages and
ndritic cells as far as their tumor tropism to hepatic Lewis Lung
arcinoma (LLC) tumors is concerned [8]. In contrast, substantial
vivo differences in tumor tropism between MDSCs (either directly
om bone marrow samples or after in vitro differentiation) and
althy bone marrow cells were not observed in our study. This
riking difference might at least partly be explained by the
nsiderable number of CD11b+Ly6G+Ly6Cint granulocytic
DSCs (about 45%) compared to CD11b+Ly6G-Ly6Chi mono-
tic MDSCs (8-13%) present in our injected MDSCs. To our
owledge, no publications are available that directly compare the
mor tropism of granulocytic versus monocytic MDSCs. A second
ssibility is that the used MDSCs are less recruited to fat pad tumors
mpared to the intrahepatic tumor model as used by Eisenstein et al.
013) [8]. Nevertheless, this latter argument seems unlikely since
1 tumors are known to generate a large number of MDSCs
0,31]. Lastly, since Eisenstein et al. used an intrahepatic LLC
odel, tumor-associated accumulation of monocytic MDSCs could
rtly overlap the liver-associated accumulation and hence, induce
lse positive results.
Overall, the use of cellular vehicles to deposit toxic agents in
mors after systemic administration requires these vehicles to
ecifically accumulate in the tumor. In the current study, relevant
mbers of injected cells were found at the tumor location, but a
bstantial off-target migration was also seen in the liver, spleen and
e lungs. Since the general trend of this off-target migration was
clining over time whereas the tumor-associated accumulation
mained constant or slowly increased, we plotted this relative shift.
he steady accumulation in the tumor until the moment of
thanasia alludes to the existence of a peak at later timepoints. We
erefore suggest that gene modified cellular vehicles that contain a
netic ON/OFF switch in the expression cassette of the therapeutic
ne would allow to switch on the expression of toxic agents when the
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his point could be determined by incorporation of reporter genes as
ngitudinal trackers [56]. Interestingly, the described ‘relative on-
rget fraction’ indicates that fresh bone marrow cells from either
althy or tumor-bearing donors have superior properties compared
cultured monocytes and macrophages. It is tempting to attribute
is property to the relatively unmanipulated state of these cells, but
nce the in vitro differentiated MDSCs exhibited a similar profile, this
planation may not suffice. Based on our former findings [57], we aim
transfect primary myeloid cells with a gene coding for IL-12.
ccessful expression of this gene near solid tumors would not only
imulate cellular immunity against tumor antigens [58], but can also
larize myeloid cells toward an anti-tumoral phenotype [59,60].
We can conclude that the accumulation of immune cells in tumors
ainly occurs via a non-specific passive process. Indeed, bone marrow
lls from healthy or tumor-bearing donors, as well as in vitro
fferentiated MDSCs, monocytes or macrophages and fixated
acrophages all demonstrate a comparable tumor-associated fluores-
nce upon intravenous injection. In addition, marked off-target
questration of injected immune cells can be seen in the liver, spleen
d the lungs. The relative on-target percentage calculation reveals that
cultured (‘fresh’) primary immune cells, followed by cultured
DSCs, had superior distribution profiles compared to cultured
onocytes and macrophages. One way or another, the off-target
igration of cellular vehicles intended for tumor targeted delivery
ould be addressed when pursuing true tumor-specific delivery.[1
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